Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (2848)	3/19/1998 4:49:00 PM
From: Tokyo VD	Respond to of 7041

Dauntless, Sorry for the confusion on the first point. I had only heard about Asensio after the stock had started to move down, so I attributed the start date as just after the Schering announcement. You are probably right that he was out doing work on the name, but I was confused by the Yahoo message that you sent us because it said that Asensio had been negative since late 1996. The timeline just seemed off (not even worth commenting on). The second point was the 3,000 patients. The two U.S. phase III studies enrolled a total of 900 patients. Approx. 300 of these patients continued into the 2,000 patient open label study (joining an additional 1,685 patients). Therefore, the total U.S. patients who've been in the Zonagen trials is roughly 2,300 patients. I can't find the other 700. Thanks for the answers to the other questions. Tokyo